Bristol-Myers Squibb Company
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BMY research report →
About the company
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism.
- CEO
- Christopher S. Boerner
- IPO
- 1972
- Employees
- 32,500
- HQ
- Princeton, NJ, US
Price Chart
Get TickerSpark's AI analysis on BMY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $124.04B
- P/E
- 17.06
- P/S
- 2.56
- P/B
- 6.19
- EV/EBITDA
- 11.56
- Div Yield
- 4.13%
- Gross Margin
- 68.75%
- Op Margin
- 25.67%
- Net Margin
- 15.01%
- ROE
- 39.05%
- ROIC
- 13.55%
- Revenue
- $48.19B · -0.22%
- Net Income
- $7.05B · 178.82%
- EPS
- $3.46 · 178.46%
- Op Income
- $12.70B
- FCF YoY
- -7.87%
- 52W High
- $62.89
- 52W Low
- $42.52
- 50D MA
- $56.96
- 200D MA
- $54.69
- Beta
- 0.23
- Avg Volume
- 11.72M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 30, 26 | YALE PHYLLIS R | other | 607.428 |
| Jun 30, 26 | Samuels Theodore R. II | other | 889.448 |
| Jun 30, 26 | Rice Derica W | other | 672.51 |
| Jun 30, 26 | McMullen Michael R. | other | 607.428 |
| Jun 30, 26 | Arduini Peter J | other | 607.428 |
| Jun 15, 26 | Haller Julia A | other | 20,460 |
| Jun 15, 26 | Haller Julia A | other | 20,460 |
| Jun 3, 26 | Short Bartie Wendy | other | 8,040 |
| Jun 3, 26 | Short Bartie Wendy | other | 3,876 |
| Jun 3, 26 | Short Bartie Wendy | other | 8,040 |
Our BMY coverage
Recent articles, reports, and earnings notes.
Want a deeper read on BMY?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.
Bristol Myers buys Nvidia's latest AI computing system for drug research
reuters.com · Jul 20
Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA
businesswire.com · Jul 20
Dimensional Fund Advisors LP Has $1.14 Billion Stock Holdings in Bristol Myers Squibb Company $BMY
defenseworld.net · Jul 20
Allspring Global Investments Holdings LLC Boosts Stake in Bristol Myers Squibb Company $BMY
defenseworld.net · Jul 18
Why the Market Dipped But Bristol Myers Squibb (BMY) Gained Today
zacks.com · Jul 16
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
zacks.com · Jul 16
Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?
zacks.com · Jul 15
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
zacks.com · Jul 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
Community Sentiment
Be the first to call it — is BMY a buy or a sell from here?